v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | NCT04359095 |
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
|
First author
Last imported at : Aug. 13, 2021, 4:30 p.m. Source : ClinicalTrials.gov |
|
Contact
Last imported at : Aug. 13, 2021, 4:30 p.m. Source : ClinicalTrials.gov |
hggaitand@unal.edu.co |
Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2020-04-24 |
Recruitment status
Last imported at : Aug. 13, 2021, 4:30 p.m. Source : ClinicalTrials.gov |
Completed |
Study design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
RCT |
Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Randomized |
Design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Parallel |
Masking
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Open label |
Center
Last imported at : March 15, 2023, 4 a.m. Source : ClinicalTrials.gov |
multi-center |
Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Treatment |
Inclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m. Source : ClinicalTrials.gov |
inclusion criteria: eligibility criteria for institutions: centralized pharmacy department which allows safe storage of drugs centralized pharmacy department that follows good clinical practice protocols for investigation and either icu capacity of at least 10 beds with available ventilatory support (volume) or intermediate care unit with at least 10 beds with partial ventilatory support inclusion criteria for participants: - age 18 years or over - positive rt-pcr for covid-19 or high suspicion of sars covid 19 - requirement of in-hospital treatment, classified in any of the following categories: mild pneumonia, defined as: - confirmed pneumonia with chest x-rays and at least 2 of the following risk factors or complications: age 60 years or over history of cardiovascular disease history of diabetes mellitus (dm) history of chronic obstructive pulmonary disease (copd) history of hypertension (ht) cancer or moderate pneumonia, defined as : - confirmed pneumonia with chest x-rays and either - criteria for in-hospital management according to the simplified confusion- respiratory rate- blood pressure- age scale (crb-65 scale) score greater than 1 or oxygen saturation lower than 90 percent without supplementary oxygen. or severe pneumonia, sepsis or septic shock, defined as: confirmed pneumonia with chest x-rays and either criteria for in-hospital management according to the simplified crb-65 scale (score greater than 1) or oxygen saturation lower than 90 percent without supplementary oxygen and any of the following: respiratory rate greater than 30 per minute need for mechanical ventilation (invasive or non-invasive) sepsis defined as organic dysfunction which can be identified by a sequential organ failure assessment score (sofa score) of at least 2 points quick sequential organ failure assessment score (qsofa) score with 2 of the following criteria: glasgow of 13 or lower, systolic blood pressure of 100 mmhg or lower and respiratory rate equal to or higher than 22 per minute arterial hypotension which persists after hydric resuscitation and requires vasopressors to maintain a mean arterial pressure greater than 65 mmhg and lactate lesser than 2 mmol/l (18 mg/dl) without hypovolemia (referred as septic shock) multiple organ failure acute respiratory distress syndrome (radiological findings compatible with bilateral infiltrates and oxygenation deficit classified as: mild (pao2/fio2 between 200 and 300), moderate (pao2/fio2 between 100 and 200) or severe (pao2/fio2 lower than 100)). exclusion criteria for participants: pregnancy known allergies to the drugs under study hepatic cirrhosis (child b or c) or hepatic abnormality manifested as transaminase levels 5 times above reference values glomerular filtration rate lesser than 30 ml/min/1.73^m2 by chronic kidney disease epidemiology collaboration (ckd-epi) formula advanced or metastatic cancer fatigue, resistance, ambulation, illnesses, and loss of weight questionnaire (frail) score of fragility greater than 3 |
Exclusion criteria
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
4 |
Funding
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Universidad Nacional de Colombia |
Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
18 |
Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
Countries
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Colombia |
Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
No restriction on type of patients |
Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
0: No restriction on type of patients |
Total sample size
Last imported at : Aug. 13, 2021, 4:30 p.m. Source : ClinicalTrials.gov |
650 |
primary outcome
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection;Mortality |
Notes
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
Phase
Last imported at : Feb. 25, 2021, 7:58 p.m. Source : ClinicalTrials.gov |
Phase 2/Phase 3 |
Arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
[{"arm_notes": "", "treatment_id": 1496, "treatment_name": "Emtricitabine+tenofovir", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 1471, "treatment_name": "Colchicine+rosuvastatin", "treatment_type": "Metabolic agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 1849, "treatment_name": "Colchicine+emtricitabine+rosuvastatin+tenofovir", "treatment_type": "Metabolic agents+antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}] |